RYTM insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Stock Options (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 28126 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. · The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. | 2026-11-18 | 2026-11-20 | 9,374 shares/units | SEC 4 | Follow |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Stock Options (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 25306 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. · The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. | 2026-11-18 | 2026-11-20 | 24,944 shares/units | SEC 4 | Follow |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Stock Options (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 8375 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. · The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. | 2026-11-18 | 2026-11-20 | 4,188 shares/units | SEC 4 | Follow |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Stock Options (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 3984 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. · The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. | 2026-11-18 | 2026-11-20 | 1,961 shares/units | SEC 4 | Follow |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 10461 · SEC code covers open-market or private transactions · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. · The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $119.75 to $120.36 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | 2026-11-18 | 2026-11-20 | ≈ $5,506,152.91 45,921 shares/units | SEC 4 | Follow |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 56382 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. | 2026-11-18 | 2026-11-20 | 9,374 shares/units | SEC 4 | Follow |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 47008 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. | 2026-11-18 | 2026-11-20 | 24,944 shares/units | SEC 4 | Follow |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 22064 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. | 2026-11-18 | 2026-11-20 | 4,188 shares/units | SEC 4 | Follow |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 17876 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. | 2026-11-18 | 2026-11-20 | 1,961 shares/units | SEC 4 | Follow |
| JEAN CHRISTOPHE Director · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Stock Options (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 0 · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026. · The options fully vested upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders. | 2026-11-17 | 2026-11-18 | 10,000 shares/units | SEC 4 | Follow |
| JEAN CHRISTOPHE Director · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 11712 · SEC code covers open-market or private transactions · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026. | 2026-11-17 | 2026-11-18 | ≈ $287,500.00 2,500 shares/units | SEC 4 | Follow |
| JEAN CHRISTOPHE Director · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 14212 · SEC code covers open-market or private transactions · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026. | 2026-11-17 | 2026-11-18 | ≈ $275,000.00 2,500 shares/units | SEC 4 | Follow |
| JEAN CHRISTOPHE Director · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 16712 · SEC code covers open-market or private transactions · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026. | 2026-11-17 | 2026-11-18 | ≈ $534,050.00 5,000 shares/units | SEC 4 | Follow |
| JEAN CHRISTOPHE Director · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 21712 · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026. | 2026-11-17 | 2026-11-18 | 10,000 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.